Brett Baker
Founder, President & CSO
Board of Directors
Microbion Corporation
Canada
Biography
Dr. Brett Baker is the founder of Microbion as well as the original formulator of the company’s mission, scientific projects, and business strategies. He identified the bismuth-thiol platform technology as a highly valuable tool in the fight against infectious disease, and successfully negotiated Microbion’s exclusive, international license in this regard. Dr. Baker is a primary physician with advanced training in cancer research. His graduate research led to the identification of the first animal homolog of the human ICAM-1 (intercellular adhesion molecule-1) molecule. ICAM-1 is a vital protein on the surface of T-cells that allows these active immune system cells to reversibly adhere to many other cell types, facilitating rapid intercellular communication in the immune system. Dr. Baker has served as the author and Principal Investigator for over $6.7 million in grants awarded to Microbion from the US Department of Defense (DOD), the National Institutes of Health (NIH), and other government agencies. He is also the author of an additional $2.5 million grant recently recommended for funding by the DOD to support Phase II human clinical studies. He led our Phase I human clinical study project, and he has received advanced training in microbial biofilm research from the Center for Biofilm Engineering at Montana State University. Dr. Baker has contributed to Microbion’s growing suite of intellectual property. He leads Microbion’s establishment of effective relationships with commercialization partners.
Research Interest
Business and Management
